- Home
- SAVA vs SNBR Comparison
SAVA vs SNBR Comparison
Compare SAVA & SNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SNBR
- Stock Information
- Founded
- SAVA 1998
- SNBR 1987
- Country
- SAVA United States
- SNBR United States
- Employees
- SAVA N/A
- SNBR N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SNBR Home Furnishings
- Sector
- SAVA Health Care
- SNBR Consumer Discretionary
- Exchange
- SAVA Nasdaq
- SNBR Nasdaq
- Market Cap
- SAVA 157.5M
- SNBR 150.1M
- IPO Year
- SAVA N/A
- SNBR 1998
- Fundamental
- Price
- SAVA $2.82
- SNBR $3.91
- Analyst Decision
- SAVA Buy
- SNBR Hold
- Analyst Count
- SAVA 2
- SNBR 3
- Target Price
- SAVA $5.00
- SNBR $8.00
- AVG Volume (30 Days)
- SAVA 1.2M
- SNBR 868.1K
- Earning Date
- SAVA 11-12-2025
- SNBR 11-05-2025
- Dividend Yield
- SAVA N/A
- SNBR N/A
- EPS Growth
- SAVA N/A
- SNBR N/A
- EPS
- SAVA N/A
- SNBR N/A
- Revenue
- SAVA N/A
- SNBR $1,440,882,000.00
- Revenue This Year
- SAVA N/A
- SNBR N/A
- Revenue Next Year
- SAVA N/A
- SNBR $1.02
- P/E Ratio
- SAVA N/A
- SNBR N/A
- Revenue Growth
- SAVA N/A
- SNBR N/A
- 52 Week Low
- SAVA $1.15
- SNBR $3.49
- 52 Week High
- SAVA $33.98
- SNBR $20.73
- Technical
- Relative Strength Index (RSI)
- SAVA 38.79
- SNBR 24.84
- Support Level
- SAVA $2.65
- SNBR $3.97
- Resistance Level
- SAVA $3.30
- SNBR $5.64
- Average True Range (ATR)
- SAVA 0.21
- SNBR 0.44
- MACD
- SAVA -0.07
- SNBR -0.06
- Stochastic Oscillator
- SAVA 18.02
- SNBR 19.77
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.